Your browser doesn't support javascript.
loading
Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency.
Bardasi, Camilla; Benatti, Stefania; Luppi, Gabriele; Garajovà, Ingrid; Piacentini, Federico; Dominici, Massimo; Gelsomino, Fabio.
Afiliação
  • Bardasi C; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
  • Benatti S; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
  • Luppi G; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
  • Garajovà I; Medical Oncology Unit, University Hospital of Parma, 43100 Parma, Italy.
  • Piacentini F; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
  • Dominici M; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
  • Gelsomino F; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
Cancers (Basel) ; 14(3)2022 Jan 28.
Article em En | MEDLINE | ID: mdl-35158931
Carcinoid Crisis represents a rare and extremely dangerous manifestation that can occur in patients with Neuroendocrine Tumors (NETs). It is characterized by a sudden onset of hemodynamic instability, sometimes associated with the classical symptoms of carcinoid syndrome, such as bronchospasm and flushing. Carcinoid Crisis seems to be caused by a massive release of vasoactive substances, typically produced by neuroendocrine cells, and can emerge after abdominal procedures, but also spontaneously in rare instances. To date, there are no empirically derived guidelines for the management of this cancer-related medical emergency, and the available evidence essentially comes from single-case reports or dated small retrospective series. A transfer to the Intensive Care Unit may be necessary during the acute setting, when the severe hypotension becomes unresponsive to standard practices, such as volemic filling and the infusion of vasopressor therapy. The only effective strategy is represented by prevention. The administration of octreotide, anxiolytic and antihistaminic agents represents the current treatment approach to avoid hormone release and prevent major complications. However, no standard protocols are available, resulting in great variability in terms of schedules, doses, ways of administration and timing of prophylactic treatments.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália